TY - JOUR T1 - Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01885-2017 SP - 1701885 AU - F. Santamaria-Martos AU - I. Benítez AU - C. Girón AU - F. Barbé AU - M.A. Martínez-García AU - L. Hernández AU - J.M. Montserrat AU - E. Nagore AU - A. Martorell-Calatayud AU - F. Campos-Rodriguez AU - J. Corral AU - V. Cabriada AU - J. Abad AU - O. Mediano AU - M.F. Troncoso AU - I. Cano-Pumarega AU - A.M. Fortuna Gutierrez AU - T. Diaz-Cambriles AU - M. Somoza-Gonzalez AU - I. Almendros AU - R. Farre AU - D. Gozal AU - M. Sánchez-de-la-Torre A2 - , Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/02/01/13993003.01885-2017.abstract N2 - The goal of this study was to assess the relationship between the severity of OSA and the levels of carcinogenesis- and tumour growth-related biomarkers, in patients with cutaneous melanoma (CM).This multicentre observational study included patients who were newly diagnosed with melanoma. The patients were classified as non-OSA (apnoea–hypopnoea index (AHI); 0–5 events/h), mild-OSA (AHI; 5–15 events/h), and moderate to severe OSA (AHI>15 events/h). Enzyme-linked immunosorbent assays (ELISAs) were performed to analyse the serum levels of hypoxia- and tumour adhesion-related biomarkers (VEGF, IL8, ICAM-1, VCAM-1), and markers of tumour aggressiveness (S100B, MIA). A logistic model adjusted for age, sex and body mass index (BMI) was fitted to each biomarker, and the AHI served as the dependent variable.A total of 360 patients were included (52.2% male, median [IQR]; 55.5 [43.8–68.0] years, AHI of 8.55 [2.8–19.5] events/h). The levels of VEGF, IL-8, ICAM-1, S100B and MIA were not related to the severity of OSA. The levels of VCAM-1 were higher in patients with OSA than those without OSA (mild OSA: OR=2.07,p=0.021; moderate-severe OSA: OR=2.35,p=0.013).In patients with cutaneous melanoma, OSA was associated with elevated circulating levels of VCAM-1 that could indicate the contribution of OSA in tumorigenesis via integrin-based adhesion.In patients with cutaneous melanoma, OSA is associated with an increased expression of a biomarker of tumorigenesisFootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Santamaria-Martos has nothing to disclose.Conflict of interest: Dr. Benitez has nothing to disclose.Conflict of interest: Dr. Girón has nothing to disclose.Conflict of interest: Dr. Barbé has nothing to disclose.Conflict of interest: Dr. Martinez-García has nothing to disclose.Conflict of interest: Dr. Hernandez has nothing to disclose.Conflict of interest: Dr. Montserrat has nothing to disclose.Conflict of interest: Dr. Nagore has nothing to disclose.Conflict of interest: Dr. Martorell-Calatayud has nothing to disclose.Conflict of interest: Dr. Campos-Rodriguez has nothing to disclose.Conflict of interest: Dr. Corral has nothing to disclose.Conflict of interest: Dr. Cabriada has nothing to disclose.Conflict of interest: Dr. Abad has nothing to disclose.Conflict of interest: Dr. Mediano has nothing to disclose.Conflict of interest: Dr. Troncoso has nothing to disclose.Conflict of interest: Dr. Cano-Pumarega has nothing to disclose.Conflict of interest: Dr. Díaz-Cambriles has nothing to disclose.Conflict of interest: Dr. Somoza-Gonzalez has nothing to disclose.Conflict of interest: Dr. Almendros has nothing to disclose.Conflict of interest: Dr. Farre has nothing to disclose.Conflict of interest: Dr. Gozal has nothing to disclose.Conflict of interest: Dr. Sánchez-de-la-Torre has nothing to disclose.Conflict of interest: Dr. Fortuna has nothing to disclose. ER -